Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 1057-1063

  Nagai, Tadashi ^a   Ohmine, Ken ^a   Fujiwara, Shin ichiro ^a   Uesawa, Mitsuyo ^a   Sakurai, Chihiro ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Farnesyltransferase inhibitor; K562; K562 RR; Leukemia; Rapamycin; Tipifarnib

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAPAMYCIN; TIPIFARNIB;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; LEUKEMIA; QUINOLONES; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 77953613476     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.011     Document Type: Article

References (32)

1. Chen G.Q., Wang L.S., Wu Y.L., Yu Y. Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacol Sin 2007, 28:1316-1324.
2. Jabbour E., Cortes J., O'Brien S., Giles F., Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007, 44(1 Suppl. 1):S25-31.
3. Fröhling S., Scholl C., Gilliland D.G., Levine R.L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005, 23:6285-6295.
4. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005, 4:77-84.
5. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 2005, 4:186-190.
6. Karp J.E., Lancet J.E., Kaufmann S.H., End D.W., Wright J.J., Bol K., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001, 97:3361-3369.
7. Lancet J.E., Gojo I., Gotlib J., Feldman E.J., Greer J., Liesveld J.L., et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007, 109:1387-1394.
8. Harousseau J.L., Lancet J.E., Reiffers J., Lowenberg B., Thomas X., Huguet F., et al. Farnesyltransferase Inhibition Global Human Trials (FIGHT) Acute Myeloid Leukemia Study Group. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007, 109:5151-5156.
9. Harousseau J.L., Martinelli G., Jedrzejczak W.W., Brandwein J.M., Bordessoule D., Masszi T., et al. A randomized phase 3 study of tipifarnib compared to best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. Blood 2009 Jun 11, [Epub ahead of print].
10. Cortes J., Albitar M., Thomas D., Giles F., Kurzrock R., Thibault A., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101:1692-1697.
11. Alsina M., Fonseca R., Wilson E.F., Belle A.N., Gerbino E., Price-Troska T., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004, 103:3271-3277.
12. Miyoshi T., Nagai T., Ohmine K., Nakamura M., Kano Y., Muroi K., et al. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochem Pharmacol 2005, 69:1585-1594.
13. Karp J.E., Flatten K., Feldman E.J., Greer J.M., Loegering D.A., Ricklis R.M., et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase I trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009, 113:4841-4852.
14. Récher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mas V.M., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
15. Récher C., Dos Santos C., Demur C., Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005, 4:1540-1549.
16. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
17. Kubonishi I., Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983, 1:105-117.
18. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 1985, 9:381-390.
19. Miyoshi T., Nagai T., Kikuchi S., Ohmine K., Nakamura M., Hanafusa T., et al. Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib. Exp Hematol 2007, 35:1358-1365.
20. Collins S.J., Gallo R.C., Gallagher R.E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977, 270:347-349.
21. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976, 17:565-577.
22. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999-2007.
23. Nagai T., Igarashi K., Akasaka J., Furuyama K., Fujita H., Hayashi N., et al. Regulation of NF-E2 activity in erythroleukemia cell differentiation. J Biol Chem 1998, 27:5358-5365.
24. Del Villar K., Urano J., Guo L., Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem 1999, 274:27010-27017.
25. Raponi M., Lancet J.E., Fan H., Dossey L., Lee G., Gojo I., et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111:2589-2596.
26. Korycka A., Smolewski P., Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 2004, 73:418-426.
27. Medeiros B.C., Landau H.J., Morrow M., Lockerbie R.O., Pitts T., Eckhardt S.G. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 2007, 21:739-746.
28. Ishizuka T., Sakata N., Johnson G.L., Gelfand E.W., Terada N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Commun 1997, 230:386-391.
29. Morley S.J., McKendrick L. Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T3 cells. J Biol Chem 1997, 272:17887-17893.
30. Miller A.L., Garza A.S., Johnson B.H., Thompson E.B. Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 2007, 7:3.
31. Hahn M., Li W., Yu C., Rahmani M., Dent P., Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005, 4:457-470.
32. Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005, 280:31101-31108.